knowledge -WSS

knowledge

author：entertainment 2025-09-05 15:43:16 - browse：52886

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug Krazati, for $4.8 billion in cash in a deal that shows the continued interest of large pharmaceutical firms in relatively small “bolt-on” acquisitions.

Bristol said that it would pay $58.00 per share for Mirati, and would hold another $12.00 per share, or a total of $1 billion, to be paid if one of two different applications for an additional use for Krazati is approved within seven years after the merger closes.

Chris Boerner, Bristol’s chief operating officer and CEO-elect, said in a statement that Mirati had several cancer drugs in development that could deliver sales in the latter half of the decade and beyond, when investors worry that Bristol will need new products to sustain its growth.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： TikTok, Instagram influencers need more rules for drug ads

WSS

Dog Aging Project founders on what lies ahead after losing funding

Medicare drug price negotiation’s day in court

Do digital therapeutics have a future in medicine?

What we need to know about Arena Bioworks

General Catalyst, Summa Health deal will turn on physician buy

FDA endorses new sterilization method for medical devices

entertainment

knowledge

entertainment

Anesthesiologist group: stop taking Ozempic before surgery

Do digital therapeutics have a future in medicine?

Novavax promises a turnaround & Lilly roils the obesity market

The inclusion problem at the heart of rehabilitation research

23andMe had bad news about my health. I wish a person had delivered it

Commercial surrogacy can be ethical, despite pope’s claims

At least 13 dead in Texas as scorching temps continue

High breast density mammograms need follow

How one medical school became remarkably diverse

Time to name cancers by genetics, not organ of origin, expert says

entertainment

Dana Farber says 6 studies to be retracted and 31 corrected

Mass General, Mayo Clinic look to monetize custom

Time to name cancers by genetics, not organ of origin, expert says

SAMSHA loosens regulations on methadone treatment centers

The real point of Kenneth Smith’s execution by nitrogen gas

Quicker fix for pulse oximeters urged during FDA public meeting

Wikipedia

focus

leisure time

focus